**Author details**

Kheir Eddine Kerboua1 \* and Kamal Djenouhat<sup>2</sup>

1 Laboratory of Immunology, Faculty of Medicine, University of Kasdi Merbah Ouargla, Algeria

2 Laboratory of Immunology, Faculty of Medicine, University of Algiers I, Algeria

\*Address all correspondence to: k.k.eddine@gmail.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**111**

*Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP100)*

[9] Rodríguez-Sanz A, Sánchez-Villanueva R, Domínguez-Ortega J, Fiandor A-M, Ruiz M-P, Trocoli F, et al. Mechanisms involved in

10.1111/aor.12954

hypersensitivity reactions to polysulfone hemodialysis membranes. Artificial Organs. 2017;**41**(11):285-295. DOI:

[10] Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. Journal of Cellular

and Molecular Medicine. 2008

[12] Pangburn MK. Alternative pathway of complement. Methods in Enzymology. 1988;**162**:648-649

[13] Platts-Mills TAE, Ishizaka K. Activation of the alternate pathway of human complement by rabbit cells. Journal of Immunology.

[14] Servais G, Walmagh J, Duchateau J.

Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50). Journal of Immunological Methods.

[15] Kazatchkine M, Hauptmann G, Nydegger U. Dosage de l'activité fonctionnelle de la voie alterne

VAH50. In: Inserm, editor. Techniques en Immunologic. Techniques du Complement. Paris: Inserm; 1985. p. 34

[16] Kazatchkine MD, Nydegger UE. The human alternative complement pathway: Biology and immunopathology of activation and regulation. Progress in

1974;**113**(1):348-358

1991;**140**(1):93-100

Allergy. 1982;**130**:193

[11] Pangburn MK. The alternative pathway. In: Ross G, editor.

Immunobiology of the Complement System. San Diego: Academic Press;

Dec;**12**(6a):2245-2254

1981. pp. 45-62

*DOI: http://dx.doi.org/10.5772/intechopen.81743*

[1] Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nature Immunology.

[2] Shih AR, Murali MR. Laboratory tests for disorders of complement and complement regulatory proteins. American Journal of Hematology.

[3] Holers VM. The spectrum of complement alternative pathwaymediated diseases. Immunological Reviews. 2008;**223**:300-316

[4] Kerboua K et al. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results. Journal of Immunoassay and Immunochemistry. 2017;**38**(2):178-189

[5] Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, et al. Diagnosis of complement alternative pathway disorders. Kidney International. 2016;**89**(2):278-288

[6] Song D, Guo WY, Wang FM, Li YZ, Song Y, Yu F, et al. Complement alternative pathway′s activation in patients with lupus nephritis. The American Journal of the Medical Sciences. 2017;**353**(3):247-257

[7] Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. A novel approach to preventing the hemolysis of paroxysmal

nocturnal hemoglobinuria: Both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood.

[8] Lewis LA, Ram S. Meningococcal disease and the complement system.

2010;**115**(11):2283-2289

Virulence. 2014;**5**(1):98-126

**References**

2010;**11**(9):785-797

2015;**90**(12):1180-1186

*Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP100) DOI: http://dx.doi.org/10.5772/intechopen.81743*
